Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways
Mingjie Liu, Yanxia Li, Chengxue Qin, Lingling Wang, Meiqi Guo, Yi Wang, Qian Zhou, Zhida Shi, Weimin Hao, Yuan Li, Baobing Zhao · 2026
Read Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways by Mingjie Liu, Yanxia Li, Chengxue Qin, Lingling Wang, Meiqi Guo, Yi Wang, Qian Zhou, Zhida Shi, Weimin Hao, Yuan Li, Baobing Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13129468.txt.
Description
Mingjie Liu and co-authors test a classic herbal formula against blood cancers called myeloproliferative neoplasms. Their 2026 paper studies diseases driven by mutated blood stem cells, with high clot risk and a chance to turn into leukemia. The formula, Fufang Huangbo, is long used for inflammation-linked illness. Its effect on these cancers was unknown.
Across several mouse models, the formula eased disease progress. It cut clot formation in one model and reversed marrow scarring in another. Network and gene studies tied its action to cell aging and inflammation. Lab checks showed it switched on an aging path through two key proteins. It also blocked two inflammatory signal paths. The authors offer the work as scientific backing for its use in these diseases.
Catalog record
| CREATOR | Mingjie Liu, Yanxia Li, Chengxue Qin, Lingling Wang, Meiqi Guo, Yi Wang, Qian Zhou, Zhida Shi, Weimin Hao, Yuan Li, Baobing Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |